By GEN News Staff
The FDA approved prucalopride (Motegrity, Shire), a once-daily, oral treatment option for adults with chronic idiopathic constipation (CIC).
Prucalopride, a selective serotonin-4 (5-HT4) receptor agonist, works by enhancing colonic peristalsis to increase bowel motility.